Kai Wang1,2, Shiyue Sun3, Guigui Zhang3, Zixian Lu3, Hui Chen3, Xia Fan3, Chunjie Gu3, Xiaohong Pan3, Qian Lin2, Oscar Chen2, Lu Cai2, Xiaozhen Dai4, Xiao Wang5, Chaosheng Lu1, Xiaoqing Yan6, Yi Tan7. 1. Department of Pediatrics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 2. Pediatric Research Institute, Department of Pediatrics, University of Louisville School of Medicine, 570 South Preston Street, Baxter-I Building Suite 304E, Louisville, KY, 40202, USA. 3. Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. 4. School of Biosciences and Technology, Chengdu Medical College, Chengdu, Sichuan, China. 5. Department of Obstetrics, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. 6. Chinese-American Research Institute for Diabetic Complications, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. yanxiaoqing1128@163.com. 7. Pediatric Research Institute, Department of Pediatrics, University of Louisville School of Medicine, 570 South Preston Street, Baxter-I Building Suite 304E, Louisville, KY, 40202, USA. yi.tan@louisville.edu.
Abstract
PURPOSE: Endothelial progenitor cells (EPCs) play a critical role in repairing damaged vessels and triggering ischemic angiogenesis, but their number is reduced and function is impaired under diabetic conditions. Improving EPC function has been considered a promising strategy to ameliorate diabetic vascular complications. In the present study, we aim to investigate whether and how CXCR7 agonist TC14012 promotes the angiogenic function of diabetic EPCs. METHODS: High glucose (HG) treatment was used to mimic the hyperglycemia in diabetes. Tube formation, cell scratch recovery and transwell assay, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and cleaved-caspase3 expression were used to evaluate the angiogenic capability, cell migration, and apoptosis of EPCs, respectively. Hind limb ischemia (HLI) model was used to appraise the ability of TC14012 in promoting diabetic ischemic angiogenesis in vivo. RESULTS: HG treatment impaired EPC tube formation and migration, and induced EPC apoptosis and oxidative damage, while TC14012 rescued tube formation and migration, and prevented HG-induced apoptosis and oxidative damage of EPCs. Furthermore, these beneficial effects of TC14012 on EPCs were attenuated by specific siRNAs against CXCR7, validating that CXCR7 is a functional target of TC14012 in EPCs. Mechanistic studies demonstrated that HG treatment reduced CXCR7 expression in EPCs, and impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation and nitric oxide (NO) production; similarly, these signal impairments in HG-exposed EPCs could be rescued by TC14012. However, the protective effects of TC14012 on tube formation and migration, Akt and eNOS phosphorylation, and NO production in HG-treated EPCs were almost completely abolished by siRNAs against CXCR7 or Akt specific inhibitor wortmannin. More importantly, in vivo study showed that TC14012 administration enhanced blood perfusion recovery and angiogenesis in the ischemic hind limb and increased the EPC number in peripheral circulation of db/db mice, demonstrating the capability of TC14012 in promoting EPC mobilization and ischemia angiogenic function. CONCLUSION: TC14012 can prevent EPCs from HG-induced dysfunction and apoptosis, improve eNOS activity and NO production via CXCR7/Akt signal pathway, and promote EPC mobilization and diabetic ischemia angiogenesis.
PURPOSE: Endothelial progenitor cells (EPCs) play a critical role in repairing damaged vessels and triggering ischemic angiogenesis, but their number is reduced and function is impaired under diabetic conditions. Improving EPC function has been considered a promising strategy to ameliorate diabetic vascular complications. In the present study, we aim to investigate whether and how CXCR7 agonist TC14012 promotes the angiogenic function of diabetic EPCs. METHODS: High glucose (HG) treatment was used to mimic the hyperglycemia in diabetes. Tube formation, cell scratch recovery and transwell assay, terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and cleaved-caspase3 expression were used to evaluate the angiogenic capability, cell migration, and apoptosis of EPCs, respectively. Hind limb ischemia (HLI) model was used to appraise the ability of TC14012 in promoting diabetic ischemic angiogenesis in vivo. RESULTS: HG treatment impaired EPC tube formation and migration, and induced EPC apoptosis and oxidative damage, while TC14012 rescued tube formation and migration, and prevented HG-induced apoptosis and oxidative damage of EPCs. Furthermore, these beneficial effects of TC14012 on EPCs were attenuated by specific siRNAs against CXCR7, validating that CXCR7 is a functional target of TC14012 in EPCs. Mechanistic studies demonstrated that HG treatment reduced CXCR7 expression in EPCs, and impaired Akt and endothelial nitric oxide synthase (eNOS) phosphorylation and nitric oxide (NO) production; similarly, these signal impairments in HG-exposed EPCs could be rescued by TC14012. However, the protective effects of TC14012 on tube formation and migration, Akt and eNOS phosphorylation, and NO production in HG-treated EPCs were almost completely abolished by siRNAs against CXCR7 or Akt specific inhibitor wortmannin. More importantly, in vivo study showed that TC14012 administration enhanced blood perfusion recovery and angiogenesis in the ischemic hind limb and increased the EPC number in peripheral circulation of db/db mice, demonstrating the capability of TC14012 in promoting EPC mobilization and ischemia angiogenic function. CONCLUSION: TC14012 can prevent EPCs from HG-induced dysfunction and apoptosis, improve eNOS activity and NO production via CXCR7/Akt signal pathway, and promote EPC mobilization and diabetic ischemia angiogenesis.
Authors: Anna Grochot-Przeczek; Jerzy Kotlinowski; Magdalena Kozakowska; Katarzyna Starowicz; Jolanta Jagodzinska; Anna Stachurska; Oscar L Volger; Karolina Bukowska-Strakova; Urszula Florczyk; Magdalena Tertil; Agnieszka Jazwa; Krzysztof Szade; Jacek Stepniewski; Agnieszka Loboda; Anton J G Horrevoets; Jozef Dulak; Alicja Jozkowicz Journal: Antioxid Redox Signal Date: 2014-02-28 Impact factor: 8.401
Authors: Alexandra Aicher; Christopher Heeschen; Ken-ichiro Sasaki; Carmen Urbich; Andreas M Zeiher; Stefanie Dimmeler Journal: Circulation Date: 2006-12-04 Impact factor: 29.690
Authors: Xiaozhen Dai; Xiaoqing Yan; Jun Zeng; Jing Chen; Yuehui Wang; Jun Chen; Yan Li; Michelle T Barati; Kupper A Wintergerst; Kejian Pan; Matthew A Nystoriak; Daniel J Conklin; Gregg Rokosh; Paul N Epstein; Xiaokun Li; Yi Tan Journal: Circ Res Date: 2017-01-30 Impact factor: 17.367
Authors: Jonathan D Newman; Anish K Vani; Jose O Aleman; Howard S Weintraub; Jeffrey S Berger; Arthur Z Schwartzbard Journal: J Am Coll Cardiol Date: 2018-10-09 Impact factor: 24.094